Relapsed Multiple Myeloma

Showing 1 - 25 of 25

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Refractory Multiple Myeloma, Relapsed Multiple Myeloma Trial in Miami (Iberdomide, Carfilzomib, Daratumumab)

Not yet recruiting
  • Refractory Multiple Myeloma
  • Relapsed Multiple Myeloma
  • Miami, Florida
    University of Miami
May 31, 2023

Elranatamab, Myeloma, Multiple Myeloma Trial in China (Elranatamab)

Recruiting
  • Elranatamab
  • +10 more
  • Fuzhou, Fujian, China
  • +18 more
Jan 18, 2023

Refractory Multiple Myeloma, Relapsed Multiple Myeloma Trial in San Francisco (Manufactured Anti-BCMA CAR-T cells, Fludarabine,

Recruiting
  • Refractory Multiple Myeloma
  • Relapsed Multiple Myeloma
  • Manufactured Anti-BCMA CAR-T cells
  • +2 more
  • San Francisco, California
    University of California, San Francisco
Jan 6, 2023

Relapsed Multiple Myeloma, Refractory Multiple Myeloma Trial in Worldwide (Dexamethasone, Daratumumab, Carfilzomib)

Completed
  • Relapsed Multiple Myeloma
  • Refractory Multiple Myeloma
  • Boca Raton, Florida
  • +112 more
Sep 9, 2022

Relapsed Multiple Myeloma Trial in Spain (Belantamab mafodotin, Carfilzomib, Dexamethasone)

Recruiting
  • Relapsed Multiple Myeloma
  • Belantamab mafodotin
  • +2 more
  • Badalona, Spain
  • +14 more
Sep 5, 2022

Relapsed Multiple Myeloma, Refractory Multiple Myeloma Trial in United States (REGN5459)

Active, not recruiting
  • Relapsed Multiple Myeloma
  • Refractory Multiple Myeloma
  • Indianapolis, Indiana
  • +6 more
Aug 16, 2022

Relapsed Multiple Myeloma, Refractory Multiple Myeloma Trial (Rapid Infusion Isatuximab)

Withdrawn
  • Relapsed Multiple Myeloma
  • Refractory Multiple Myeloma
  • Rapid Infusion Isatuximab
  • (no location specified)
Jul 3, 2022

Relapsed Multiple Myeloma, Refractory Multiple Myeloma Trial (Elotuzumab, Selinexor, and Dexamethasone (ESd))

Withdrawn
  • Relapsed Multiple Myeloma
  • Refractory Multiple Myeloma
  • Elotuzumab, Selinexor, and Dexamethasone (ESd)
  • (no location specified)
Apr 27, 2022

Relapsed Multiple Myeloma Trial in Italy (Isatuximab-dexamethasone)

Active, not recruiting
  • Relapsed Multiple Myeloma
  • Ancona, Italy
  • +14 more
Mar 24, 2022

Relapsed Multiple Myeloma, Refractory Multiple Myeloma Trial in Canada, United States (Ixazomib, Lenalidomide, Dexamethasone)

Completed
  • Relapsed Multiple Myeloma
  • Refractory Multiple Myeloma
  • Little Rock, Arkansas
  • +23 more
Feb 24, 2022

Relapsed Multiple Myeloma in France in Context of Carfilzomib

Completed
  • Relapsed Multiple Myeloma
    • Le Mans, France
      Centre Hospitalier Du Mans
    Mar 8, 2022

    Acute Leukemia, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia/Lymphoma Trial in Minneapolis (drug, radiation, biological)

    Recruiting
    • Acute Leukemia
    • +24 more
    • Minneapolis, Minnesota
      Masonic Cancer Center at University of Minnesota
    Nov 4, 2021

    Relapsed Multiple Myeloma, Refractory Multiple Myeloma Trial in United States (ION251)

    Recruiting
    • Relapsed Multiple Myeloma
    • Refractory Multiple Myeloma
    • Birmingham, Alabama
    • +11 more
    Oct 13, 2021

    Relapsed Multiple Myeloma, Refractory Multiple Myeloma Trial in Boston, Danvers, Newton (Nivolumab, Ixazomib, Dexamethasone)

    Active, not recruiting
    • Relapsed Multiple Myeloma
    • Refractory Multiple Myeloma
    • Boston, Massachusetts
    • +2 more
    May 14, 2021

    Non-interventional Study on Salvage Auto in Relapsed Myeloma

    Completed
    • Relapsed Multiple Myeloma
      • Paris, France
        Hématologie Clinique, Hôpital Saint Antoine
      Jan 19, 2021

      Relapsed Multiple Myeloma Trial in Worldwide (Dexamethasone, Lenalidomide, Carfilzomib)

      Completed
      • Relapsed Multiple Myeloma
      • Scottsdale, Arizona
      • +126 more
      Dec 21, 2018

      Relapsed Multiple Myeloma Trial in Odense (peptides derived from antiapoptotic proteins)

      Completed
      • Relapsed Multiple Myeloma
      • peptides derived from antiapoptotic proteins
      • Odense, Denmark
        Department of Haematology, Odense University Hospital
      Aug 30, 2018

      Hematologic Cancer, Relapse Leukemia, Relapsed Adult ALL Trial in Montreal (GLIDE)

      Unknown status
      • Hematologic Cancer
      • +8 more
      • GLIDE
      • Montreal, Quebec, Canada
        CIUSSS d l'Est-de-l'Île-de-Montréal
      Dec 4, 2017

      Relapsed Multiple Myeloma Trial in Canada, United States (Carfilzomib, Lenalidomide, Dexamethasone)

      Completed
      • Relapsed Multiple Myeloma
      • Long Beach, California
      • +11 more
      Apr 28, 2017

      Relapsed Multiple Myeloma, End-stage Renal Disease Trial in Australia, Canada, United States (Carfilzomib)

      Completed
      • Relapsed Multiple Myeloma
      • End-stage Renal Disease
      • Detroit, Michigan
      • +12 more
      Apr 28, 2017

      Relapsed Multiple Myeloma Trial in Iowa City (ATRA, Celecoxib, Itraconazole)

      Completed
      • Relapsed Multiple Myeloma
      • Iowa City, Iowa
        University of Iowa Hospitals and Clinics
      Feb 20, 2017

      Relapsed Multiple Myeloma, Refractory Multiple Myeloma, Waldenstrom Macroglobulinemia Trial in United States (MLN0128)

      Completed
      • Relapsed Multiple Myeloma
      • +2 more
      • San Francisco, California
      • +5 more
      Jul 31, 2013

      Relapsed Multiple Myeloma, Plateau Phase Multiple Myeloma Trial in Boston, Rochester (2-methoxyestradiol)

      Completed
      • Relapsed Multiple Myeloma
      • Plateau Phase Multiple Myeloma
      • Boston, Massachusetts
      • +1 more
      Feb 25, 2009